Controlled, partially exfoliated, self-supported functionalized flexible graphitic carbon foil for ultrasensitive detection of SARS-CoV-2 spike protein

Adeel, Muhammad; Asif, Kanwal; Canzonieri, Vincenzo; Barai, Hasi Rani; Rahman, Mujibur; Daniele, Salvatore; Rizzolio, Flavio

doi:10.1016/j.snb.2022.131591

Cited by 24 publications

(22 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the insulating character of the biological components immobilized onto the electrode surface and the more steric/conformational restrictions of the proteins, the electron transfer was inhibited. Hence, a decrease in current with the shift in the redox peaks was observed, similarly to the results presented in previous studies [ 6 , 28 , 34 , 40 , 41 ].…”

Section: Resultssupporting

confidence: 90%

Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2

et al. 2022

View full text Add to dashboard Cite

After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was developed and applied for rapid, reliable, sensitive and selective detection of the SARS-CoV-2 S1 protein. To detect the SARS-CoV-2 virus, targeting of the spike S1 protein was achieved herein by using S1 protein-specific capture antibody (Cab-S1) immobilized screen-printed electrode (SPE) in combination with the electrochemical impedance spectroscopy (EIS) technique. With the impedimetric immunosensor, the detection limit for S1 protein in buffer medium was found to be 0.23 ng/mL (equal to 23.92 amol in 8 µL sample) in the linear concentration range of S1 protein from 0.5 to 10 ng/mL. In the artificial saliva medium, it was found to be 0.09 ng/mL (equals to 9.36 amol in 8 µL sample) in the linear concentration range of S1 protein between 0.1 and 1 ng/mL. The selectivity of the impedimetric immunosensor toward S1 protein was tested against influenza hemagglutinin antigen (HA) in the buffer medium as well as in artificial saliva.

show abstract

Section: Resultssupporting

confidence: 90%

Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Accordingly, anti-SARS-CoV-2 capture probe-based immunosensors have received potential interest for screening SARS-CoV-2 protein antigens. Adeel et al developed an ultrasensitive and label-free electrochemical SP sensing platform based on a functionalized self-supported graphitic carbon foil electrode (Figure 5a) [69].…”

Section: Detection Of Spike Proteinsmentioning

confidence: 99%

Progress in Electrochemical Biosensing of SARS-CoV-2 Virus for COVID-19 Management

Rahman

2022

Chemosensors

Self Cite

View full text Add to dashboard Cite

Rapid and early diagnosis of lethal coronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important issue considering global human health, economy, education, and other activities. The advancement of understanding of the chemistry/biochemistry and the structure of the SARS-CoV-2 virus has led to the development of low-cost, efficient, and reliable methods for COVID-19 diagnosis over “gold standard” real-time reverse transcription-polymerase chain reaction (RT-PCR) due to its several limitations. This led to the development of electrochemical sensors/biosensors for rapid, fast, and low-cost detection of the SARS-CoV-2 virus from the patient’s biological fluids by detecting the components of the virus, including structural proteins (antigens), nucleic acid, and antibodies created after COVID-19 infection. This review comprehensively summarizes the state-of-the-art research progress of electrochemical biosensors for COVID-19 diagnosis. They include the detection of spike protein, nucleocapsid protein, whole virus, nucleic acid, and antibodies. The review also outlines the structure of the SARS-CoV-2 virus, different detection methods, and design strategies of electrochemical SARS-CoV-2 biosensors by highlighting the current challenges and future perspectives.

show abstract

“…), which sends analog data to the processing system that converts them into digital data [ 9 ]. The biosensors developed in the diagnosis of COVID-19, according to the target molecule identified in the sample, can detect high specificity antibodies in serum or high-affinity molecules of the SARS-CoV-2 virus [ 10 , 11 , 12 ]. Biosensor development for SARS-CoV-2 diagnostic is a challenge to researchers.…”

Section: Introductionmentioning

confidence: 99%

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

et al. 2022

View full text Add to dashboard Cite

SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.

show abstract

Controlled, partially exfoliated, self-supported functionalized flexible graphitic carbon foil for ultrasensitive detection of SARS-CoV-2 spike protein

Cited by 24 publications

References 64 publications

Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2

Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2

Progress in Electrochemical Biosensing of SARS-CoV-2 Virus for COVID-19 Management

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

Contact Info

Product

Resources

About